Skip to main content
. Author manuscript; available in PMC: 2020 May 12.
Published in final edited form as: Cancer Lett. 2018 Nov 10;442:483–490. doi: 10.1016/j.canlet.2018.11.008

Figure 5.

Figure 5.

Hypothesis. Enzalutamide promotes AR interacting with Beclin 1 complex, to inactive its activity in mediating growth factor ERK signaling transit via decreasing P13P generation. In the upper panel, Enzalutamide could increase AR interaction with Beclin 1 complex. In the lower panel of means Beclin 1 complex could transfer growth factor from activation to inactivation status. Because Enzalutamide suppresses Beclin 1 complex’s activity, therefore, the ERK growth factor signal could be continuely activated, and cells become more “resistant”, while ERKI combined with Enzalutamide could re-sensitize cell resistant. ERKI: ERK Inhibitor.